The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    410

  • View Count
    8822

Example Insights

Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Context Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Development Pipeline Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Pipeline Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Key Insights
Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Developer Landscape Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Technology Providers Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Clinical Trial Analysis Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Partnerships & Collaborations
Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-List Of CROs & CMOs Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Promotional Strategies Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Market Attractiveness Analysis 	Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030-Futuer Forecast

 

Overview

The first monoclonal antibody, Orthoclone OKT3®, was approved in 1986 by the FDA. Since then, a number of antibody therapeutics (more than 100) have been marketed for the treatment of patients suffering from various disease indications, primarily malignant tumors and other rare disorders. Despite the success, these drugs are associated with several limitations, such as increased patient resistance and a general lack of understanding of in vivo mechanisms of action. The aforementioned challenges and impending patent expiries of some of the blockbuster monoclonal antibodies have compelled the researchers and pharmaceutical companies to redesign these drugs and / or find new analogues. To further improve the specificity, efficacy and safety of monoclonal antibodies, the focus has gradually shifted towards the development of next generation recombinant antibodies, such as antibody-drug conjugates (ADCs), bispecific and multispecific antibodies, and antibody fragments and antibody-like proteins (ALPs).

Bispecific antibodies are a novel class of antibody therapeutics that act by simultaneously binding two separate and unique antigens (or different epitopes of the same antigen). The primary mechanism of action of these therapeutics involves redirection of immune effector cells for effective killing of cancer cells by antibody-dependent cell mediated cytotoxicity (ADCC) and other cytotoxic mechanisms, such as antibody dependent cellular phagocytosis (ADCP) and complement dependent cytotoxicity (CDC). Having unique biological and pharmacological properties, as well as their availability in different formats, bispecific antibodies have emerged as promising agents for therapeutic use. Advancements related to protein and antibody engineering techniques have led to the production of close to 50 new formats in the recent years. 

Till date, two bispecific antibodies, namely Blincyto® (2014) and Hemlibra® (2017), have been approved for therapeutic use. It is worth mentioning that, in 2019 (till September), Blincyto® and Hemlibra® generated revenues worth USD 232 million and USD 930 million, respectively. The growing popularity and therapeutic potential of bispecific antibodies can also be correlated to an exponential increase in the number of clinical trials; the cumulative count of trials has increased from 51 studies in 2014 to over 300 studies in 2019 (till September). More than 300 bispecific drug candidates are currently in clinical / preclinical stages. In fact, multiple licensing agreements, between drug developers and technology providers, have also been inked in the past few years to advance the development of pipeline drug candidates.

Scope of the Report

The “Bispecific Antibody Therapeutics Market (4th Edition), 2019-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of bispecific antibody therapeutics, including information on drug developers, phase of development (marketed, clinical, and preclinical / discovery) of the pipeline candidates, target antigen, type of antibody format, mechanism of action, target disease indication(s), therapeutic area, broader disease segment, route of administration, mode of administration and patient segment. 
  • A comprehensive list of novel technology platforms that are either currently available or being developed by various firms for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration the early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above)development activity based on the technology (in terms of the number of drugs across different phases of development), number of partnerships established related to the technology and size of the developer company. In addition, it consists of a schematic world map representation, highlighting the geographical locations of technology developers engaged in this domain.
  • Detailed profiles of marketed and clinical stage (phase II and phase III) bispecific antibody therapeutics. Each profile features an overview of the drug, details of the developer, along with its financial performance, mechanism of action and targets, dosage information, current clinical development status, development process, as well as details on annual sales (wherever available).
  • Key takeaways from the bispecific antibody therapeutics pipeline, featuring a [A] grid analysis, representing the distribution of the pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, [B] a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules, [C] a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies and [D] the chapter also includes an insightful summary representation using the logos of different industry stakeholders, highlighting the distribution of companies based on the company size. 
  • An analysis of the big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and, target therapeutic area.
  • An analysis of recent partnerships and collaboration agreements inked in this domain since 2016, covering research collaborations, product and technology licensing agreements, product development and commercialization agreements, manufacturing agreements, mergers / acquisitions, joint ventures, product development agreements and other deals.
  • A review on the key steps involved and challenges associated with the manufacturing of bispecific antibodies. In addition, it includes a list of contract manufacturing organizations (CMOs) and contract research organizations (CROs). The chapter also highlights the key considerations for bispecific antibody developers while selecting a suitable CRO / CMO.
  • A clinical trial analysis of ongoing and planned studies related to bispecific antibody therapeutics, taking into consideration a number of relevant parameters, including trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®. It includes a detailed comparison of both the drugs based on the information available on their respective websites, such as patient support offerings, informative downloadable content, and product visibility in scientific conferences.
  • A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis that highlights the relative impact of each SWOT parameter on the overall market.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for bispecific antibody therapeutics, for the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the evolution of the market for the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders), [B] different mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others), [C] key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1α x IL-1β, Psl x PcrV, TNF-α x HSA and VEGF-A x ANG-2), [D] type of antibody formats (asymmetric, fragments, symmetric and others), [E] key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical) and [F] key geographical regions (North America, Europe and Asia Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Martin Steiner (Chief Executive Officer, Synimmune)
  • Ludger Große-Hovest (Chief Scientific Officer, Synimmune) 
  • Jane Dancer (Chief Business Officer, F-Star)
  • Siobhan Pomeroy (Senior Director, Business Development, Cytom X)
  • Yinjue Wang (Associate Director, Process Development, Innovent Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the market for bispecific antibody therapeutics and its likely evolution in the mid to long term.

Chapter 3 provides a general overview of antibodies, including their historical background, structure, and the different types of antibodies available, along with their mechanisms of action. In addition, the chapter highlights the evolution of antibody-based therapeutics over the last few years. It also features a discussion on bispecific antibodies, elaborating on the different bispecific formats that are currently available, mechanisms of action of various products / product candidates and their applications.

Chapter 4 provides information on over 300 bispecific antibody drug candidates that are either approved or in different stages of development (clinical and preclinical / discovery). It features an analysis of drug developers on basis of various parameters, such as year of establishment, company size and geographical location, phase of development (marketed, clinical, and preclinical / discovery stage) of the pipeline molecules, target antigens, type of antibody format (symmetric antibody format, asymmetric antibody format, fragments and others), mechanism of action, target disease indication(s), therapeutic area, broader disease segment (oncology / non-oncology), route of administration and patient segment. 

Chapter 5 includes a list of innovative technology platforms that are either currently available, or being developed by various firms, for the generation of bispecific antibody therapeutics, along with detailed profiles of key technologies. Each profile contains details on the technology, including the pipeline molecules being developed using the technology, its advantages and partnerships established related to the technology. The chapter also includes an insightful competitiveness analysis, featuring a three-dimensional bubble representation that highlights the key technologies that are being used for the development of bispecific antibodies, taking into consideration early stage (discovery, preclinical, IND and phase I) and late stage (phase II and above) the development activity based on the technology (in terms of the number of drugs across different phases of development) and the size of the developer company. In addition, it features a schematic world map representation, highlighting the geographical locations of technology developers, along with the symbol representation for drug portfolio for each technology. 

Chapter 6 provides detailed profiles of marketed drugs and mid to late stage (phase II and phase III) candidates. Each profile provides information on the drug overview, including route of administration, developer, highest phase of development, primary indication, therapeutic area, special designation (if any), key targets, mechanism of action, technology used, current status of development, information on clinical studies and key clinical trial results of the drug, antibody format (if available) and construct (if available). It also includes an overview of the developer, its financial details and annual sales of the drug, in case of approved drugs. 

Chapter 7 is a compilation of key insights featuring a grid analysis, representing the distribution of pipeline (on the basis of mechanisms of action of product candidates) across different therapeutic areas and stages of development, a five-dimensional spider-web analysis, highlighting the most popular mechanisms of action based on a number of relevant parameters, including number of bispecific antibodies in early stage (phase I) and late stage of development (phase II and above), number of ongoing clinical trials, target therapeutic areas and the number of companies that are developing these molecules and a two-dimensional scattered plot competitiveness analysis, for the various target combinations for clinical-stage bispecific antibodies. It also presents a detailed logo landscape of the companies engaged in the development of bispecific antibody-based products, distributed based on the status of development of their pipeline candidates and size of the company (small, mid-sized and large companies).

Chapter 8 highlights big biopharma players engaged in this domain, featuring a heat map based on various parameters, such as number of bispecific antibody therapeutics under development, target antigen, type of antibody format, mechanism of action and target therapeutic area.

Chapter 9 features the different partnership models and the most common forms of deals / agreements that have been inked amongst players in this market between 2016 and 2019 (till September). It also presents an analysis of the various collaboration agreements signed in this domain, based on the year of partnership, type of partnership, therapeutic area most active developers (in terms of number of partnerships), most active contract manufacturers (in terms of number of manufacturing agreements) and regional analysis

Chapter 10 highlights the key manufacturing steps involved, and challenges associated with the manufacturing of bispecific antibodies. In addition, it consists a list of CMOs and CROs involved in this domain along with the details on their headquarters, year of establishment and other specific information, such as scale of operation of CMOs and research services offered by CROs. The chapter also highlights the key points that bispecific antibody developers need to consider while or selecting a suitable CRO / CMO.

Chapter 11 presents an analysis of the various clinical trials of bispecific antibodies registered across the world (which have last update of 2019). The analysis was done for clinical trials across various parameters, such as trial registration year, trial recruitment status, trial phase, trial design, disease indication(s), focus therapeutic area, most active industrial and non-industrial players, and geographical location of the trial based on the number of trails and number of patients enrolled.

Chapter 12 is a review of regulatory guidelines issued by the ICH, WHO and FDA related to the development of bispecific antibodies. In addition, it provides details related to the responses of the various pharmaceutical industries to the FDA guidelines.

Chapter 13 highlights the key promotional strategies that are being implemented by the developers of the marketed bispecific antibodies, namely Blincyto® and Hemlibra®, and comparison of both the drugs based on the information available on their respective websites. The promotional aspects covered in the chapter include the drug overview, details provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings, informative downloadable content, and product visibility in scientific conferences.

Chapter 14 provides a discussion on important industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis, that highlights the relative impact of each SWOT parameter on the overall bispecific antibody therapeutic market.

Chapter 15 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of bispecific antibody therapeutics that are either marketed or in advanced stages of clinical development (phase II and phase III). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key therapeutic areas (genetic disorders, hematological malignancies, autoimmune disorders, infectious diseases, inflammatory disorders, eye disorders and skin disorders), key mechanisms of action (T-cell retargeting / activation, cytokines retargeting / neutralization, dual ligands blocking and others), [C] key targets (CD3 x CD19, CD30 x CD16A, Factor IXa x Factor X, IL-13 x IL-4, IL-17A x Albumin, IL-17A x IL-17F, IL-1α x IL-1β, Psl x PcrV, TNF-α x HSA and VEGF-A x ANG-2), [D] type of antibody format (asymmetric, fragments, symmetric and others), [E] key players (AbbVie, Affibody, Affimed, Amgen, AstraZeneca, Merck, Roche, Sanofi and Taisho Pharmaceutical), and [F] key geographical regions (North America, Europe and Asia Pacific).

Chapter 16 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the bispecific antibody therapeutics industry.

Chapter 17 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Martin Steiner (Chief Executive Officer, Synimmune), Ludge Große-Hovest (Founder and Chief Scientific Officer, Synimmune), Jane Dancer (Chief Business Officer, F-Star), Siobhan Pomeroy (Senior Director, Business Development, Cytom X) and Yinjue Wang (Associate Director, Process Development, Innovent Biologics). 

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Functions of an Antibody
3.5. Mechanism of Action of an Antibody
3.6. Concept of Monoclonal Antibodies
3.7. Antibody Therapeutics
3.8. Historical Evolution of Antibody Therapeutics

3.9. Types of Advanced Antibody Therapeutics
3.9.1. Fc Engineered and Glycoengineered Antibodies
3.9.2. Antibody Fragments
3.9.3. Fusion Proteins
3.9.4. Intrabodies
3.9.5. Bispecific Antibodies
 
3.10. Bispecific Antibody Formats 
3.10.1. Single-Chain-based Formats (Fc Independent Antibody Formats)
3.10.1.1. Tandem scFvs (single-chain variable fragments) and Triple bodies
3.10.1.2. Bispecific Single-Domain Antibody Fusion Proteins
3.10.1.3. Diabodies / Diabody Derivatives
3.10.1.4. Fusion Proteins
3.10.1.5. Fusion Proteins Devoid of Fc Regions

3.10.2. Immunoglobulin G (IgG)-based Formats (Fc Dependent Antibody Formats)
3.10.2.1. Quadromas
3.10.2.2. Knobs-Into-Holes
3.10.2.3. Dual Variable Domain Ig
3.10.2.4. IgG-scFv
3.10.2.5. Two-in-one or Dual Action Fab (DAF) Antibodies
3.10.2.6. Half Molecule Exchange
3.10.2.7. κλ- Bodies
 
3.11. Mechanisms of Action of Bispecific Antibodies 
3.11.1. Retargeting Immune Effectors (NK Cells and T Cells) to Tumor Cells
3.11.2. Directly Targeting Malignant / Tumor Cells
3.11.3. Retargeting of Toxins 
3.11.5. Targeting Tumor Angiogenesis
3.11.6. Other Mechanisms
 
3.12. Applications of Bispecific Antibodies
 
4. MARKET OVERVIEW
4.1.  Chapter Overview
4.2.  Bispecific Antibody Therapeutics: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geographical Location
 
4.3.  Bispecific Antibody Therapeutics: Clinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Antigen
4.3.3. Analysis by Type of Antibody Format
4.3.4. Analysis by Mechanism of Action
4.3.5. Analysis by Disease Indication
4.3.6. Analysis by Therapeutic Area
4.3.7. Analysis by Broader Disease Segment
4.3.8. Analysis by Route of Administration
4.3.9. Analysis by Mode of Administration 
4.3.10. Analysis by Patient Segment

4.4.  Bispecific Antibody Therapeutics: Early Stage Pipeline
4.4.1. Analysis by Phase of Development
4.4.2. Analysis by Target Antigen
4.4.4. Analysis by Mechanism of Action
4.4.5. Analysis by Therapeutic Area
4.4.6. Analysis by Broader Disease Segment

4.6.  Bispecific Antibody Therapeutics: Combination Therapy Candidates
4.7. Bispecific Antibody Therapeutics: Non-Industry Players
4.8. Emerging Novel Antibody Therapeutic Modalities
 
5. BISPECIFIC ANTIBODY THERAPEUTICS: TECHNOLOGY PLATFORMS
5.1. Chapter Overview
5.2. Bispecific Antibody Therapeutics: List of Technology Platforms
5.3. Bispecific Antibody Therapeutics: Technology Platform Profiles
 
5.3.1. Bispecific T-cell Engager (BiTE®) (Amgen)
5.3.1.1. Overview
5.3.1.2. Technology Details
5.3.1.3. Structure of BiTE® Bispecific Antibodies
5.3.1.4. Pipeline of BiTE® Bispecific Antibodies
5.3.1.5. Advantages of BiTE® Bispecific Antibodies
5.3.1.6. Partnerships and Collaborations
 
5.3.2. DuoBody® (Genmab)
5.3.2.1. Overview
5.3.2.2. Technology Details
5.3.2.3. Structure of DuoBody® Bispecific Antibodies
5.3.2.4. Pipeline of DuoBody® Bispecific Antibodies
5.3.2.5. Advantages of DuoBody® Bispecific Antibodies
5.3.2.6. Partnerships and Collaborations 
 
5.3.3. Xmab™ Antibody Engineering Platform (Xencor)
5.3.3.1. Overview
5.3.3.2. Technology Details
5.3.3.3. Pipeline of Xmab™ Bispecific Antibodies
5.3.3.4. Advantages of Xmab™ Bispecific Antibodies
5.3.3.5. Partnerships and Collaborations
 
5.3.4. WuXibodyTM Bispecific Engineering Platform (WuXi Biologics)
5.3.4.1. Overview
5.3.4.2. Pipeline of WuXibodyTM Bispecific Antibodies
5.3.4.3. Advantages of WuXibodyTM Bispecific Antibodies
5.3.4.4. Partnerships and Collaborations
 
5.3.5. Anticalin® (Pieris Pharmaceuticals)
5.3.5.1. Overview
5.3.5.2. Structure of Anticalin® Bispecific Fusion Proteins
5.3.5.3. Pipeline of Anticalin® Bispecific Fusion Proteins
5.3.5.4. Advantages of Anticalin® Bispecific antibody Platform
5.3.5.5. Partnerships and Collaborations
 
5.3.6. Azymetric™ (Zymeworks)
5.3.6.1. Overview
5.3.6.2. Technology Details
5.3.6.3. Structure of Azymetric™ Bispecific Antibodies
5.3.6.4. Pipeline of Azymetric™ Bispecific Antibodies
5.3.6.5. Advantages of the AzymetricTM Bispecific Antibodies 
5.3.6.6. Partnerships and Collaborations
 
5.4. Geographical Distribution of Technology Providers 
5.5. Bispecific Antibody Technology Platforms: Comparative Analysis
 
6. DRUG PROFILES
6.1. Chapter Overview
6.2. Marketed Drug Profiles
 
6.2.1. Blincyto™ / Blinatumomab / AMG103 / MT103 (Amgen)
6.2.1.1. Company Overview
6.2.1.1.1. Financial Performance
6.2.1.2. Drug Overview
6.2.1.2.1. Mechanism of Action and Targets
6.2.1.2.2. Dosage
6.2.1.2.3. Current Development Status
6.2.1.2.4. Development Process
6.2.1.2.5. Annual Sales
 
6.2.2. Hemlibra® / Emicizumab / RG6013 / ACE910 / RO5534262 (Chugai Pharmaceutical / Roche)
6.2.2.1. Company Overview
6.2.2.1.1. Financial Performance
6.2.2.2. Drug Overview
6.2.2.2.1. Mechanism of Action and Targets
6.2.2.2.2. Dosage
6.2.2.2.4. Development Process
6.2.2.2.5. Annual Sales
 
6.3. Late Stage Drug Profiles
6.4. RG7716 / RO6867461 / Faricimab (Roche / Genentech)
6.4.1  Drug Overview
6.5. Ozoralizumab / TS-152 / ATN103 (Ablynx / Eddingpharm / Taisho Pharmaceuticals) 
6.5.1  Drug Overview
6.6.  ABT-165 (AbbVie)
6.6.1 Overview of Drug, Current Development Status and Clinical Results
6.7. ABY-035 (Affibody)
6.7.1. Drug Overview 
6.8.  AFM13 (Affimed)
6.8.1 Drug Overview 
6.9.  AMG 570 / MEDI0700 (Amgen)
6.9.1. Drug Overview
6.10. KN026 (Alphamab)
6.10.1. Drug Overview
6.11. KN046 (Alphamab)
6.11.1. Drug Overview
6.12.  M1095 / ALX-0761 (Merck / Ablynx / Avillion)
6.12.1. Drug Overview
6.13. M7824 / Bintrafusp Alfa (Merck / GlaxoSmithKline)
6.13.1. Drug Overview
6.14. MCLA-128 (Merus)
6.14.1. Drug Overview 
6.15. MEDI3902 / Gremubamab (MedImmune /AstraZeneca)
6.15.1. Drug Overview 
6.16. MEDI7352 (AstraZeneca)
6.16.1. Drug Overview 
6.17. REGN1979 (Regeneron)
6.17.1. Drug Overview 
6.18. ZW25 (Zymeworks)
6.18.1. Drug Overview 
 
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. Bispecific Antibody Therapeutics: Analysis by Therapeutic Area and Phase of Development
7.3.  Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action
7.4. Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations 
7.4.1 Key Parameters
7.5. Logo Landscape: Analysis of Developers by Company Size
 
8. BENCHMARK ANALYSIS: BIG PHARMA PLAYERS
8.1.  Chapter Overview
8.2.  Top Pharmaceutical Companies
8.2.1.  Analysis by Target Antigen
8.2.2. Analysis by Type of Antibody Format
8.2.3. Analysis by Mechanism of Action
8.2.4. Analysis by Therapeutic Area
8.2.5. Analysis by Type of Partnership
 
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bispecific Antibody Therapeutics: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Therapeutic Area
9.3.4. Most Active Developers: Analysis by Number of Partnerships
9.3.5. Most Active Contract Manufacturers: Analysis by Number of Manufacturing Agreements
9.3.6. Regional Analysis
9.3.7. Intercontinental and Intracontinental Agreements
 
10. CONTRACT SERVICES FOR BISPECIFIC ANTIBODY THERAPEUTICS
10.1. Chapter Overview
10.2. Manufacturing of Bispecific Antibody Therapeutics
10.2.1. Key Manufacturing Considerations and Challenges
10.2.2. Contract Manufacturing Organizations (CMOs)
10.2.2.1. Introduction to CMOs
10.2.2.2. Bispecific Antibody Therapeutics: List of CMOs 
 
10.2.3. Contract Research Organizations (CROs)
10.2.3.1. Introduction to CROs
10.2.3.2. Bispecific Antibody Therapeutics: List of CROs
 
10.3. Key Considerations for Selecting a Suitable CMO / CRO Partner
 
11. CLINICAL TRIAL ANALYSIS 
11.1. Chapter Overview
11.2. Methodology
11.3. Bispecific Antibody Therapeutics: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Recruitment Status
11.3.3. Analysis by Trial Phase
11.3.4. Analysis by Trial Design
11.3.5. Analysis by Disease Indication
11.3.6. Analysis by Therapeutic Area
11.3.7. Most Active Players
11.3.8. Analysis by Number of Clinical Trials and Geography
11.3.9. Analysis by Enrolled Patient Population and Geography
 
12. CASE STUDY: REGULATORY GUIDELINES FOR BISPECIFIC ANTIBODIES
12.1. Chapter Overview
12.2. Guidelines Issued by Regulatory Authorities
12.2.1. US Food and Drug Administration (FDA)
12.2.1.1. Pharma Companies Response to the FDA Draft Guidance
 
12.2.2. World Health Organization (WHO)
12.2.3. The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use
 
13. CASE STUDY: PROMOTIONAL / MARKETING STRATEGIES
13.1. Chapter Overview
13.2. Overview of Channels Used for Promotional Campaigns
13.3. Summary: Product Website Analysis
13.4. Summary: Patient Support Services and Informative Downloads
 
13.5. Promotional Analysis: Blincyto™
13.5.1. Drug Overview
13.5.2. Product Website analysis
13.5.2.1. Messages for Healthcare Professionals
13.5.2.1.1. For MRD Positive B‑cell precursor ALL 
13.5.2.1.2. For Relapsed or Refractory B-cell precursor ALL 
13.5.2.2. Message for Patients
13.5.3. Patient Support Services and Informative Downloads
13.5.4. Other Promotional Strategies
13.5.4.1. Presence in Conferences
 
13.6. Promotional Analysis:  Hemlibra®
13.6.1. Drug Overview
13.6.2. Product Website Analysis
13.6.2.1. Messages for Healthcare Professionals
13.6.2.1.1. For Hemophilia A without Factor VIII Inhibitors
13.6.2.1.2. For Hemophilia A with Factor VIII Inhibitors
13.6.2.3. Messages for Patients
13.6.3. Patient Support Services and Informative Downloads
13.6.3.1. Co-pay Program
13.6.3.2. Independent Co-pay Assistance Foundation
13.6.3.3. Genentech Patient Foundation
13.6.4. Other Promotional Strategies
13.6.4.1. Presence in Conferences
 
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6.  Concluding Remarks
 
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology and Key Assumptions
 
15.4. Overall Bispecific Antibody Therapeutics Market, 2019-2030
15.4.1. Bispecific Antibody Therapeutics Market: Analysis by Therapeutic Area
15.4.2. Bispecific Antibody Therapeutics Market: Analysis by Mechanism of Action
15.4.3. Bispecific Antibody Therapeutics Market: Analysis by Target Antigen
15.4.4. Bispecific Antibody Therapeutics Market: Analysis by Antibody Format
15.4.5. Bispecific Antibody Therapeutics Market: Analysis by Key Players
15.4.6. Bispecific Antibody Therapeutics Market: Analysis by Geography
15.5. Bispecific Antibody Market: Value Creation Analysis
15.6. Bispecific Antibody Therapeutics Market: Product-wise Sales Forecasts
 
15.6.1. Blincyto
15.6.1.1. Target Patient Population
15.6.1.2. Sales Forecast
15.6.1.3. Net Present Value
15.6.1.4. Value Creation Analysis
 
15.6.2. Hemlibra
15.6.2.1. Target Patient Population
15.6.2.2. Sales Forecast
15.6.2.3. Net Present Value
15.6.2.4. Value Creation Analysis
 
15.6.3. RG7716
15.6.3.1. Target patient Population
15.6.3.2. Sales Forecast
15.6.3.3. Net Present Value
15.6.3.4. Value Creation Analysis
 
15.6.4. Ozoralizumab
15.6.4.1. Target Patient Population
15.6.4.2. Sales Forecast
15.6.4.3. Net Present Value
15.6.4.4. Value Creation Analysis
 
15.6.5. ABY-035
15.6.5.1. Target Patient Population
15.6.5.2. Sales Forecast
15.6.5.3. Net Present Value
15.6.5.4. Value Creation Analysis
 
15.6.6. AFM13
15.6.6.1. Target Patient Population
15.6.6.2. Sales Forecast
15.6.6.3. Net Present Value
15.6.6.4. Value Creation Analysis
 
15.6.7. M1095
15.6.7.1. Target Patient Population
15.6.7.2. Sales Forecast
15.6.7.3. Net Present Value
15.6.7.4. Value Creation Analysis
 
15.6.8. MEDI3902
15.6.8.1. Target Patient Population
15.6.8.2. Sales Forecast
15.6.8.3. Net Present Value
15.6.8.4. Value Creation Analysis
 
15.6.9. ABT-981
15.6.9.1. Target Patient Population
15.6.9.2. Sales Forecast
15.6.9.3. Net Present Value
15.6.9.4. Value Creation Analysis
 
15.6.10. SAR156597
15.6.10.1. Target Patient Population
15.6.10.2. Sales Forecast
15.6.10.3. Net Present Value
15.6.10.4. Value Creation Analysis
 
16. CONCLUDING REMARKS
 
17. EXECUTIVE INSIGHTS
17.1.  Chapter Overview
17.2.  CytomX Therapeutics
17.2.1.  Company Snapshot 
17.2.2.  Interview Transcript: Siobhan Pomeroy, Senior Director, Business Development (Q3 2017)
 
17.3.  F-star
17.3.1.  Company Snapshot 
17.3.2.  Interview Transcript: Jane Dancer, Chief Business Officer (Q3 2017)
 
17.4.  Innovent Biologics
17.4.1.  Company Snapshot 
17.4.2.  Interview Transcript: Yinjue Wang, Associate Director, Process Development (Q3 2017)
 
17.5.  Synimmune
17.4.1.  Company Snapshot 
17.4.2.  Interview Transcript: Ludger Große-Hovest, Chief Scientific Officer, and Martin Steiner, Chief Executive Officer
 
18. APPENDIX 1: TABULATED DATA
 
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1. History of Evolution of Antibodies 
Figure 3.2. Basic Structure of an Antibody
Figure 3.3. Mechanisms of Action of Antibody-based Therapeutics 
Figure 3.4. Revenues of the Top 15 Drugs, 2018 (USD Billion)
Figure 3.5. Symmetric and Asymmetric Bispecific Antibodies
Figure 4.1. Bispecific Antibody Developers: Distribution by Year of Establishment
Figure 4.2. Bispecific Antibody Developers: Distribution by Company Size
Figure 4.3. Bispecific Antibody Developers: Distribution by Geographical Location
Figure 4.4. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Phase of Development
Figure 4.5. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Target Antigen
Figure 4.6. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Type of Antibody Format
Figure 4.7. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mechanism of Action
Figure 4.8. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Disease Indication
Figure 4.9. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Therapeutic Area
Figure 4.10. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Broader Disease Segment
Figure 4.11. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Route of Administration
Figure 4.12. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mode of Administration
Figure 4.13. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Patient Segment
Figure 4.14. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Phase of Development 
Figure 4.15. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Target Antigen
Figure 4.16. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Mechanism of Action
Figure 4.17. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Disease Indication
Figure 4.18. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Therapeutic Area
Figure 4.19. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Broader Disease Segment
Figure 5.1. Structure of BiTE® Bispecific Antibody 
Figure 5.2. Structure of DuoBody® Bispecific Antibody
Figure 5.3. Structure of Anticalin® Bispecific Fusion Proteins
Figure 5.4. Structure of Azymetric™ Bispecific Fusion Proteins
Figure 5.5  Bispecific Antibody Technology Providers: Geographical Distribution
Figure 5.6. Bispecific Antibody Technology Platforms: 3-Dimensional Comparative Bubble Analysis 
Figure 6.1. Amgen: Annual Revenues, 2014-9M 2019 (USD Billion)
Figure 6.2. Blincyto®: Annual Sales, 2015-9M 2019 (USD Million)
Figure 6.3. Chugai Pharmaceutical: Annual Revenues, 2014-9M 2019 (JPY Billion)
Figure 7.1. Bispecific Antibody Therapeutics: Distribution by Therapeutic Area and Phase of Development
Figure 7.2. Bispecific Antibody Therapeutics: Spider-Web Analysis based on Mechanism of Action
Figure 7.3. Bispecific Antibody Therapeutics: Two-Dimensional Scatter Plot Analysis based on Target Combinations
Figure 7.4. Logo Landscape: Distribution of Developers by Company Size
Figure 8.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 8.2. Big Pharma Players: Distribution by Type of Target Antigen
Figure 8.3. Big Pharma Players: Distribution by Type of Antibody Format
Figure 8.4. Big Pharma Players: Distribution by Mechanism of Action
Figure 8.5. Big Pharma Players: Distribution by Therapeutic Area
Figure 8.5. Big Pharma Players: Heat Map Analysis of Other Big Players
Figure 9.1. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.4. Partnerships and Collaborations: Most Active Industrial Players
Figure 9.5. Prtnerships and Collaborations: Most Active Non-Industrial Players
Figure 9.6. Partnerships and Collaborations: Most Active Contract Manufacturers
Figure 9.7. Partnerships and Collaborations: Regional Distribution
Figure 9.8. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1. Clinical Trial Analysis: Distribution by Trial Registration Year, 2014-2019  
Figure 11.2. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Recruitment Status 
Figure 11.3. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Phase of Development 
Figure 11.4. Clinical Trial Analysis: Distribution by Trial Design
Figure 11.5. Clinical Trial Analysis: Distribution by Disease Indication
Figure 11.6. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 11.7. Clinical Trial Analysis: Most Active Industry Players
Figure 11.8. Clinical Trial Analysis: Most Active Non-Industry Players
Figure 11.9. Clinical Trial Analysis: Geographical Distribution of Number of Clinical Trials 
Figure 11.10. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population 
Figure 12.1. FDA Considerations for Development of Bispecific Antibodies 
Figure 13.1. Channels Used for Promotional Campaigns
Figure 13.2. Summary: Product Website Analysis
Figure 13.3. Summary: Patient Support Services and Informative Downloads
Figure 13.4. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, BLAST Study Results) 
Figure 13.5. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, TOWER Study Results)
Figure 13.6. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, Ph (+) Relapsed / Refractory B-cell Precursor ALL)
Figure 13.7. Blincyto®: Product Website Analysis (Messages for Healthcare Professionals, Relapsed / Refractory B-cell Precursor ALL (Pediatrics))
Figure 13.8. Blincyto®: Product Website Analysis (Messages for Patients)
Figure 13.9. Blincyto®: Amgen Assist 360 Nurse Ambassador
Figure 13.10. Blincyto®: Presence in Conferences
Figure 13.11. Hemlibra®: Product Website Analysis (Messages for Healthcare Professionals, Hemophilia A without Factor VIII Inhibitors)
Figure 13.12. Hemlibra®: Product Website Analysis (Messages for Healthcare Professionals, Hemophilia A with Factor VIII Inhibitors)
Figure 13.13. Hemlibra®: Product Website Analysis (Messages for Patients)
Figure 13.14. Hemlibra®: Presence in Conferences
Figure 14.1. Bispecific Antibody Therapeutics: SWOT Analysis 
Figure 14.2. Comparison of SWOT Factors: Harvey Ball Analysis
Figure 15.1. Overall Bispecific Antibody Therapeutics Market, 2019-2030: Base Scenario (USD Million)
Figure 15.2. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2019, 2025 and 2030 (USD Million)
Figure 15.3. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2019, 2025 and 2030 (USD Million)
Figure 15.4. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2019, 2025 and 2030 (USD Million)
Figure 15.5. Bispecific Antibody Therapeutics Market: Distribution by Antibody Format, 2019, 2025 and 2030 (USD Million)
Figure 15.6. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2019, 2025 and 2030 (USD Million)
Figure 15.7. Bispecific Antibody Therapeutics Market: Distribution by Geographical Regions, 2019, 2025 and 2030 (USD Million)
Figure 15.8. Blincyto® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.9. Hemlibra® Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.10. RG7716 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.11. Ozoralizumab Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.12. ABY-035 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.13. AFM13 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.14. M1095 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.15. MEDI3902 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.16. ABT-981 Sales Forecast (Till 2030): Base Scenario (USD Million)
Figure 15.17. SAR156597 Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

Table 3.1. Isotypes of Mammalian Antibodies
Table 3.2. Mechanisms of Action of Therapeutic Antibodies 
Table 3.3. Top Therapeutic Antibodies, 2018
Table 4.1. Bispecific Antibody Therapeutics: Information on Developer Specifications
Table 4.2. Bispecific Antibody Therapeutics: Information on Developer(s), Technology Used, Phase of development, Target antigens and Antibody Format
Table 4.3. Bispecific Antibody Therapeutics: Information on Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 4.4. Bispecific Antibody Therapeutics: Information on Route of Administration, Mode of Administration and Patient Segment
Table 4.5. Bispecific Antibody Therapeutics: Information on Developer(s), Technology used, Phase of Development, Target Antigens, Mechanism of Action, Disease Indication, Therapeutic Area and Broader Disease Segment
Table 4.6. Bispecific Antibody Therapeutics: Combination Therapy Candidates Information on Developer(s), Drug Name and NCT Number
Table 4.7. Bispecific Antibody Therapeutics: Information on Non-Industry Players
Table 4.8 List of Other Emerging Multispecific Drug Candidates
Table 5.1. Bispecific Antibody Therapeutics: List of Technology Platforms
Table 5.2. BiTE® Bispecific Antibodies: Development Pipeline
Table 5.3. BiTE® Bispecific Antibodies: Partnerships and Collaborations 
Table 5.4. DuoBody® Bispecific Antibodies: Development Pipeline
Table 5.5. DuoBody® Bispecific Antibodies: Partnerships and Collaborations 
Table 5.6. XmAb™ Bispecific Antibodies: Development Pipeline
Table 5.7. Xmab™ Bispecific Antibodies: Partnerships and Collaborations 
Table 5.8. WuXibodyTM Bispecific Antibodies: Development Pipeline
Table 5.9. WuXibodyTM Bispecific Antibodies: Partnerships and Collaborations
Table 5.10. Anticalin® Bispecific Fusion Proteins: Development Pipeline
Table 5.11. Anticalin® Bispecific Fusion Proteins: Partnerships and Collaborations
Table 5.12. Azymetric™ Bispecific Antibodies: Development Pipeline
Table 5.13. Azymetric™ Bispecific Antibodies: Partnerships and Collaborations
Table 6.1. Amgen: Bispecific Antibody Product Portfolio
Table 6.2. Chugai Pharmaceutical: Bispecific Antibody Product Portfolio
Table 6.3. Drug Profile: RG7716
Table 6.4. Drug Profile: Ozoralizumab
Table 6.5. Drug Profile: ABT-165
Table 6.6. Drug Profile: ABY-035
Table 6.7. Drug Profile: AFM13
Table 6.8. Drug Profile: AMG 570
Table 6.9. Drug Profile: KN026
Table 6.10. Drug Profile: KN046
Table 6.11. Drug Profile: M1095
Table 6.12. Drug Profile: M7824
Table 6.13. Drug Profile: MCLA-128
Table 6.14. Drug Profile: MEDI3902
Table 6.15. Drug Profile: MEDI7352
Table 6.16. Drug Profile: REGN1979
Table 6.17. Drug Profile: ZW25
Table 7.1. Bispecific Antibody Therapeutics: Spider-Web Analysis (Input Data)
Table 9.1. Bispecific Antibody Therapeutics: Partnerships and Collaborations, 2016-2019
Table 10.1. List of Bispecific Antibody CMOs: Information on Company Specifications
Table 10.2. List of Bispecific Antibody CMOs: Information on Scale of Operation
Table 10.3. List of Bispecific Antibody CROs: Information on Company Specifications
Table 10.4. List of Bispecific antibody CROs: Information Type of Service
Table 10.5 Comparison of Key Factors for the Selection of Contract Service Provider: Harvey Ball Analysis 
Table 13.1. Blincyto®: Drug Overview  
Table 13.2. Hemlibra®: Drug Overview  
Table 14.1. Bispecific Antibody Therapeutics: List of CMOs
Table 17.1. CytomX Therapeutics: Key Highlights
Table 17.2. F-star: Key Highlights
Table 17.3. Innovent Biologics: Key Highlights
Table 17.4. Synimmune: Key Highlights
Table 18.1. Revenues of the Top 15 Therapeutic Antibodies, 2018 (USD Billion)
Table 18.2. Bispecific Antibody Developers: Distribution by Year of Establishment
Table 18.3. Bispecific Antibody Developers: Distribution by Company Size
Table 18.4. Bispecific Antibody Developers: Distribution by Geographical Location
Table 18.5. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Phase of Development
Table 18.6. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Target Antigen
Table 18.7. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Type of Antibody Format
Table 18.8. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mechanism of Action
Table 18.9. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Disease Indication
Table 18.10. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Therapeutic Area
Table 18.11. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Broader Disease Segment
Table 18.12. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Route of Administration
Table 18.13. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Mode of Administration
Table 18.14. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Patient Segment
Table 18.15. Bispecific Antibody Therapeutics, Clinical Pipeline: Distribution by Dosing Frequency
Table 18.16. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Phase of Development 
Table 18.17. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Target Antigen
Table 18.18. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Mechanism of Action
Table 18.19. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Therapeutic Area
Table 18.20. Bispecific Antibody Therapeutics, Early Stage Pipeline: Distribution by Broader Disease Indication
Table 18.21. Amgen: Annual Revenues, 2014-H1 2019 (USD Billion)
Table 18.22. Blincyto®: Annual Sales, 2015-H1 2019 (USD Million)
Table 18.23. Chugai Pharmaceutical: Annual Revenues, 2014-H1 2019 (JPY Billion)
Table 18.24. Partnerships and Collaborations: Cumulative Trend by Year, 2016-2019
Table 18.25. Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.26. Partnerships and Collaborations: Distribution by Therapeutic Area
Table 18.27. Partnerships and Collaborations: Most Active Developers
Table 18.28. Partnerships and Collaborations: Most Active Contract Manufacturers
Table 18.29. Partnerships and Collaborations: Regional Distribution
Table 18.30. Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 18.31. Clinical Trial Analysis: Distribution by Trial Registration Year, 2014-2019  
Table 18.32. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Recruitment Status 
Table 18.33. Clinical Trial Analysis: Distribution of Number of Trials and Patients Enrolled by Phase of Development 
Table 18.34. Clinical Trial Analysis: Distribution by Trial Design
Table 18.35. Clinical Trial Analysis: Distribution by Disease Indication
Table 18.36. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 18.37. Clinical Trial Analysis: Most Active Industry Players
Table 18.38. Clinical Trial Analysis: Most Active Non-Industry Players
Table 18.39. Clinical Trial Analysis: Geographical Distribution of Number of Clinical Trials 
Table 18.40. Clinical Trial Analysis: Geographical Distribution of Enrolled Patient Population 
Table 18.41. Overall Bispecific Antibody Therapeutics Market, 2019-2030: Conservative, Base and Optimistic Scenario (USD Million)
Table 18.42. Bispecific Antibody Therapeutics Market: Distribution by Target Antigen, 2019, 2025 and 2030 (USD Million)
Table 18.43. Bispecific Antibody Therapeutics Market: Distribution by Type of Antibody Format, 2019, 2025 and 2030 (USD Million)
Table 18.44. Bispecific Antibody Therapeutics Market: Distribution by Mechanism of Action, 2019, 2025 and 2030 (USD Million)
Table 18.45. Bispecific Antibody Therapeutics Market: Distribution by Therapeutic Area, 2019, 2025 and 2030 (USD Million)
Table 18.46. Bispecific Antibody Therapeutics Market: Distribution by Key Players, 2019, 2025 and 2030 (USD Million)
Table 18.47. Bispecific Antibody Therapeutics Market: Distribution by Geographical Regions, 2019, 2025 and 2030 (USD Million)
Table 18.48. Blincyto®: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.49. Hemlibra®: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.50. RG7716: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.51. Ozoralizumab: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.52. ABY-035: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.53. AFM13: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.54. M1095: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.55. MEDI3902: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.56. ABT-981: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)
Table 18.57. SAR156597: Sales Forecast, 2019-2030, Conservative, Base and Optimistic Scenario (USD Million)

Listed Companies

  1. 3P Biopharmaceuticals
  2. Ab Studio
  3. AbbVie
  4. AbCellera
  5. AbClon
  6. ABL Bio
  7. Ablynx
  8. Abpro
  9. Abveris
  10. Abzena
  11. Abzyme Therapeutics
  12. Adicet Bio
  13. Adimab
  14. Advaxis
  15. Affibody
  16. Affimed
  17. AGC Biologics
  18. Agensys
  19. Agenus
  20. AgonOx
  21. Akeso Biopharma
  22. Alcami
  23. Aldevron
  24. Alexion Pharmaceuticals
  25. Alissa Pharma
  26. Allergan
  27. Alligator Bioscience
  28. Alphamab Oncology
  29. Altor BioScience
  30. Ambrx
  31. Amgen
  32. Amunix
  33. AnaptysBio
  34. Anogen
  35. Antibody Solutions
  36. AP Biosciences
  37. Aptevo Therapeutics
  38. ARBELE
  39. Array BioPharma (Now acquired by Pfizer)
  40. Astellas Pharma
  41. AstraZeneca
  42. Atreca
  43. AURA Biotechnologies
  44. Avacta
  45. AvantGen
  46. Avidity Biosciences
  47. Avillion
  48. Axcellerate Pharma
  49. Baliopharm
  50. Barbara Ann Karmanos Cancer Institute
  51. Bayer
  52. BeiGene
  53. Benhealth Biopharmaceutical
  54. Betta Pharmaceuticals
  55. BioFactura
  56. BioInvent
  57. BIOMUNEX Pharmaceuticals
  58. BioNTech
  59. Bio-Synthesis
  60. Biotecnol
  61. Biotest
  62. Biotheus
  63. BiVictriX Therapeutics
  64. bluebird bio
  65. Boehringer Ingelheim
  66. Brigham and Women’s Hospital (BWH)
  67. Bristol-Myers Squibb
  68. Calico
  69. Cancer Research UK
  70. Catalent Biologics
  71. Celgene
  72. CELLSCRIPT
  73. Celonic
  74. Centre Leon Berard
  75. ChemPartner
  76. Chiome Bioscience
  77. Christian Doppler (CD) Laboratory
  78. Chugai Pharmaceutical
  79. CinnaGen
  80. CMC Biologics
  81. Cobra Biologics
  82. Compass Therapeutics
  83. Complix
  84. Covagen
  85. Creative Biolabs
  86. Creative Biostructure
  87. Crescendo Biologics
  88. CStone Pharmaceuticals
  89. CytomX Therapeutics
  90. Cytovance® Biologics
  91. Daiichi Sankyo
  92. Dana-Farber Cancer Institute
  93. DCPrime
  94. Denali Therapeutics
  95. Dong-A ST
  96. Dragonfly Therapeutics
  97. Dualogics
  98. Eddingpharm
  99. Eli Lilly
  100. EMD Serono
  101. Emergent BioSolutions
  102. EnGeneIC
  103. EngMab
  104. EpimAb Biotherapeutics
  105. Exelixis
  106. F-star
  107. Fuda Cancer Hospital
  108. FUJIFILM Diosynth Biotechnologies
  109. Fusion Antibodies
  110. FZata
  111. GEMoaB
  112. Genedata
  113. Genentech
  114. GENERON
  115. Genmab
  116. Gilead Sciences
  117. GlaxoSmithKline
  118. Glenmark Pharmaceuticals
  119. Glycotope
  120. GO Therapeutics
  121. Goodwin Biotechnology
  122. Greffex
  123. Gritstone Oncology
  124. GT Biopharma
  125. GTP Technology
  126. Gustave Roussy
  127. Hanmi Pharmaceutical
  128. Harbour BioMed
  129. Harpoon Therapeutics
  130. HEC Paris
  131. Henlix Biotech
  132. ICON
  133. IGM Biosciences
  134. I-Mab Biopharma
  135. Immatics
  136. Immune Biosolutions
  137. Immune Design
  138. Immune Pharmaceuticals
  139. Immunex
  140. ImmuNext
  141. Immunocore
  142. Immunomedics
  143. Incyte
  144. Inhibrx
  145. Innate Pharma
  146. Innovent Biologics
  147. Inovio Pharmaceuticals
  148. Institute for Research in Biomedicine (IRB) Barcelona
  149. Invenra
  150. IONTAS
  151. IQVIA
  152. Janssen
  153. Johnson & Johnson
  154. Just mention University of California San Diego
  155. JW Pharmaceutical
  156. Kaken Pharmaceutical
  157. KBI Biopharma
  158. Kymab
  159. Lava Therapeutics
  160. Lazarex Cancer Foundation
  161. LeadArtis
  162. LEO Pharma
  163. LG Chem Life Sciences
  164. LifeArc
  165. Ligand Pharmaceuticals
  166. Light Chain Bioscience
  167. Lonza
  168. Luye Pharma Group
  169. M2Gen
  170. MAB Discovery
  171. MabPlex
  172. MabVax Therapeutics
  173. MacroGenics
  174. Massachusetts General Hospital (MGH)
  175. MediaPharma
  176. MedImmune
  177. Memorial Sloan Kettering Cancer Center
  178. Merck
  179. Mereo BioPharma
  180. Meridian Life Science
  181. Merrimack Pharmaceuticals
  182. Merus
  183. Millegen
  184. MilliporeSigma
  185. Molecular Partners
  186. MorphoSys
  187. Morphotek
  188. NanoString
  189. Nantes University Hospital
  190. National Cancer Institute (NCI)
  191. National Institutes of Health
  192. Navarrabiomed
  193. Neovii Biotech
  194. NextCure
  195. NJCTTQ
  196. Northwestern University
  197. Novartis
  198. Novasep
  199. Novimmune
  200. Numab
  201. OncoMed Pharmaceuticals
  202. Ono Pharmaceutical
  203. OriMAbs
  204. OSE Immunotherapeutics
  205. Ossianix
  206. Pfizer
  207. PharmAbcine
  208. Pieris Pharmaceuticals
  209. Pierre Fabre
  210. Premas Biotech
  211. ProMab Biotechnologies
  212. Provention Bio
  213. Pure Biologics
  214. Pure MHC
  215. PX'Therapeutics
  216. QIMR Berghofer Medical Research Institute
  217. Regeneron Pharmaceuticals
  218. Rentschler Biotechnologie
  219. Rice University
  220. Roche
  221. Roger Williams Medical Center
  222. Sanofi
  223. SATT Sud-Est
  224. Sea Lane Biotechnologies
  225. Seattle Genetics
  226. Selexis
  227. SemaThera
  228. SENJU Pharmaceutical
  229. Servier
  230. Simcere
  231. Sound Biologics
  232. Stanford University
  233. Sutro Biopharma
  234. Swedish Orphan Biovitrum (Sobi™)
  235. Syapse
  236. Synimmune
  237. SystImmune
  238. Taisho Pharmaceutical
  239. Takara Bio
  240. Takeda Pharmaceutical
  241. Tango Therapeutics
  242. Tasly Biopharma
  243. Tempus
  244. TeneoBio
  245. TESARO
  246. TG Therapeutics
  247. The Hebrew University of Jerusalem
  248. The Institute for Protein Design (IPD)
  249. The Johns Hopkins University School of Medicine
  250. The University of Texas MD Anderson Cancer Center
  251. The Wistar Institute
  252. Theradex Oncology
  253. Tilos Therapeutics
  254. TOT BIOPHARM
  255. TRACON Pharmaceuticals
  256. Trianni
  257. TRIGR Therapeutics
  258. Tufts University School of Medicine
  259. UCLA AIDS Institute
  260. University of California
  261. University of Chicago
  262. University of Kentucky Markey Cancer Center
  263. University of Michigan
  264. University of Minnesota
  265. University of North Carolina
  266. University of Virginia
  267. University of Zurich
  268. Vall d’Hebron Institute of Oncology
  269. Weizmann Institute of Science
  270. Wisconsin Alumni Research Foundation
  271. WuXi AppTec
  272. WuXi Biologics
  273. Xencor
  274. XOMA
  275. Y-Biologics
  276. Y-mAbs Therapeutics
  277. Yuhan
  278. YUMAB
  279. YZY Biopharma
  280. Zai Lab
  281. Zebra Biologics
  282. Zhejiang Teruisi Biopharmaceutical
  283. Zymeworks
  284. Zyngenia

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com